

Clinical-biochemical and Fibroelastometric Results of the Mare's Milk Application in Non-Alcoholic Steat hepatitis

Resultados clínico-bioquímicos y fibroelastométricos de la aplicación de la leche de yegua en la esteatohepatitis no alcohólica

Bakytzhan Bimbetov^{1*} <https://orcid.org/0000-0001-8309-0897>

Nasrulla Shanazarov¹ <https://orcid.org/0000-0002-2976-259X>

Saule Aitbaeva² <https://orcid.org/0000-0002-1309-286X>

Abay Bakytzhanuly² <https://orcid.org/0000-0001-7816-7327>

Gulmira Utepbergenova³ <https://orcid.org/0000-0002-1877-5264>

¹The Medical Centre Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Nur-Sultan. The Republic of Kazakhstan.

²JSC Medical University of Astana. Nur-Sultan. The Republic of Kazakhstan.

³Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkistan. The Republic of Kazakhstan.

*The corresponding author: bimbetov2010@mail.ru

ABSTRACT

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world, representing the hepatic component of metabolic syndrome, and currently affects an average of 20–33% of the adult population. Non-alcoholic steatohepatitis (NASH) is a severe form of NAFLD and is a consequence of overweight, obesity, and metabolic syndrome.

Objective: The study aimed to evaluate the effectiveness of the use of freeze-dried mare's milk in NASH.

Methods: Clinical-biochemical, ultrasound, and fibroelastometric research methods were used in NASH patients receiving mare's milk in comparison with the control groups.

Results: The result of the study demonstrates noticeable gain not only in the clinical symptoms of the disease but also in the laboratory and instrumental indicators, as well as health improvement and a decrease in symptoms of concomitant pathology.

Taking mare's milk not only normalized liver biochemical parameters but also decreased cholesterol metabolism (total cholesterol, LDL, TG), the degree of liver steatosis, and existing hepatomegaly declined too. This pleiotropic effect of mare's milk points to the pathogenetic feasibility for the use of

Saumal in NAFLD, including NASH.

Conclusions: Addressing the problems of healthy nutrition in NASH, mare's milk can be considered as a pathogenetically justified, highly effective, and affordable natural therapeutic and prophylactic agent. The value of the product is determined by its multicomponent balanced qualitative composition. Hepatoprotective, hypocholesterolemic, and lipotropic properties of mare's milk in this pathology are marked.

Keywords: non-alcoholic steatohepatitis; mare's milk; hepatoprotective properties; hypocholesterolemic properties; lipotropic properties.

RESUMEN

Introducción: La enfermedad del hígado graso no alcohólico es la enfermedad hepática más común en el mundo, representa el componente hepático del síndrome metabólico y actualmente afecta a un promedio de 20 a 33 % de la población adulta. La esteatohepatitis no alcohólica es una forma grave de hígado graso no alcohólico y es una consecuencia del sobrepeso, la obesidad y el síndrome metabólico.

Objetivo: Evaluar la efectividad del uso de leche de yegua liofilizada en hígado graso no alcohólico.

Métodos: Se utilizaron métodos de investigación clínico-bioquímicos, ecográficos y fibroelastométricos en pacientes con hígado graso no alcohólico que recibieron leche de yegua en comparación con los grupos de control.

Resultados: El resultado del estudio demuestra una ganancia notable no solo en los síntomas clínicos de la enfermedad, sino también en los indicadores de laboratorio e instrumentales, así como una mejora de la salud y una disminución de los síntomas de la enfermedad concomitante.

La ingesta de leche de yegua no solo normalizó los parámetros bioquímicos del hígado, sino que también disminuyó el metabolismo del colesterol (colesterol total, LDL, TG), el grado de esteatosis hepática y la hepatomegalia existente también disminuyeron. Este efecto pleiotrópico de la leche de yegua apunta a la viabilidad patogénica del uso de Saumal en hígado graso no alcohólico, incluida la esteatohepatitis no alcohólica.

Conclusión: Al abordar los problemas de una nutrición saludable en la enfermedad hígado graso no alcohólico, la leche de yegua se puede considerar como un agente terapéutico y profiláctico natural patogénicamente justificado, altamente efectivo y asequible. El valor del producto está determinado por su composición cualitativa equilibrada multicomponente. Las propiedades hepatoprotectoras, hipocolesterolemicas y lipotrópicas de la leche de yegua en esta enfermedad son marcadas.

Palabras clave: esteatohepatitis no alcohólica; leche de yegua; propiedades hepatoprotectoras; propiedades hipocolesterolemicas; propiedades lipotrópicas.

Recibido: 20/01/2021

Aceptado: 15/03/2021

Introduction

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of liver disease in the USA, affecting an estimated 30% of the population and associated with metabolic syndrome.^(1,2) The severe form of NAFLD is non-alcoholic steatohepatitis (NASH), which has a profound relationship with overweight, obesity, and metabolic syndrome. An unhealthy lifestyle and diet, and decreased physical activity play an important role in the development and progression of NAFLD.^(3,4) Also, the role of intestinal microflora in the development of metabolic disorders and metabolic-associated liver damage, which is NASH, has been proven.^(5,6,7,8)

Key development mechanisms of NASH are the accumulation of free fatty acids, triglycerides, and activation of lipid peroxidation in the liver, which leads to the toxic intermediate products build-up that stimulate the development of inflammation and fibrotic lesion.^(3,5,9)

A basic condition for the treatment and prevention of NASH is a low-calorie diet, restricted in saturated fatty acids (SFA), cholesterol, fructose, and simple carbohydrates, but high in polyunsaturated fatty acids (PUSFA), pre- and probiotics, and natural antioxidants.^(3,5,6,7,10) In this regard, there is an opinion, that mare's milk (Saumal) is a perfect finding in NASH diet therapy. Saumal is not only an optimal dietary supplement but also has a high therapeutic potential generally in NAFLD.

The healing qualities of mare's milk have been known for a long time.^(11,12,13,14,15,16,17,18,19) In various countries of the world, mare's milk is positioned as an effective remedy for problems with digestion and liver.^(11,12,13) Mare's milk possesses not only nutritional but also medicinal properties. Its regular use relieves or eliminates the symptoms of diseases of the digestive system, it is effective in chronic liver diseases, including hepatitis.^(11,12,13)

The study was carried out with the use of Saumal freeze-dried mare's milk (SMM) produced by "Eurasia Invest Ltd" LLP (Karaganda region, Kazakhstan), where large-scale production of SMM was established with the participation of the German horse breeding farm Hans Zollmann using an innovative freeze-drying technology in strict compliance with the European quality standard.^(11,12,20)

The study had the aim of assessing the effectiveness of the use of mare's milk in NASH based on clinical, biochemical, and fibroelastometric studies.

Methods

The work was carried out in 3 clinical centers: the Corporate Foundation “Nazarbayev University Medical Center” (Nur-Sultan, Kazakhstan), the Hospital of the Medical Center of the Department of Presidential Affairs of the Republic of Kazakhstan (Nur-Sultan, Kazakhstan), and at the Department of Internal Medicine of the Kazakh-Russian Medical University (Almaty, Kazakhstan), possessing all the necessary conditions for conducting this scientific research.

Within the framework of this study, the ethical principles of conducting biomedical research of the Republic of Kazakhstan, national and international guidelines on the ethics of research with human participants as a trial subject are followed. The ethical principles of the Declaration of Helsinki for the conduct of medical research with the participation of a human as a research subject are observed. Preliminary approval of the local ethical committee of the Corporate Foundation “University Medical Center” LLC “Nazarbayev University” dated September 25, 2017, was received.

The study was carried out on 74 NASH patients aged 36 to 60 years after the prior informed consent of all patients. The study involved 35 men and 39 women. The study is multicenter, open-label, comparative, controlled, and randomized. As a result of randomization, the patients were divided into three groups:

- 1) main group 1 (n = 28) - NASH patients who took only Saumal freeze-dried mare's milk;
- 2) main group 2 (n = 27) - NASH patients who took SMM "Saumal" in combination with ursodeoxycholic acid (UDCA "Ursosan"),
- 3) control group (n = 19) - NASH patients who took ursosan as monotherapy as hepatoprotection.

To study clinical symptomatology, the main NASH syndromes were selected, namely: asthenic, pain, and dyspeptic, and for the study of laboratory parameters-transaminases (ALT, AST), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (GGT), bilirubin, cholesterol, low density lipoproteins (LDL), high density lipoproteins (HDL), triglycerides (TG) and glucose. Biochemical blood tests were performed on an “Architectc 8000” biochemical analyzer (Abbott, USA). For greater clarity, biochemical studies of NASH patients were carried out after 2 weeks, and after a month from the start of treatment, and at the end of treatment.

Among other things, investigated were the standard ultrasound parameters of the hepatobiliary system before and after the end of the reception of SMM “Saumal”. Ultrasound examinations of the liver, biliary system, pancreas, and spleen were carried out using ultrasound scanners with an abdominal sensor from well-known companies Philips (Netherlands), Sony (Japan), Siemens (Germany). The study was carried out before the start of treatment and at the end of treatment.

Fibroelastometry of liver tissue to determine the stage of fibrosis and the degree of steatosis was carried

out on a "Fibroscan 502 Touch CAP" unit (France) fitted with an ultrasound transducer for non-invasive determination of the stage of fibrosis by the method of transient elastometry and by measuring the attenuation of ultrasound: Controlled Attenuation Parameter (CAPTM) - to determine the degree of steatosis. Fibroelastometry was also performed before and 2 months after the commencement of treatment.

Statistical analysis was performed using SPSS for Windows version 23.0 (SPSS: IBM, Armonk, NY) and Microsoft Excel-2013. A two-way t-test and odds ratio (OR) with 95% confidence intervals were used. The value $p < 0.05$ was found to be significant.

The work was carried out within the scope of a scientific grant (URN AR051355855) of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan on the priority "Science of Life" after obtaining the preliminary consent of patients for the study and the conclusions of the local ethical committee. The scientific project is registered in the ClinicalTrials.gov database.

Results and Discussion

When conducting clinical, laboratory, and instrumental studies in NASH patients, an improvement in the clinical symptomatology of the disease was noted in all treated patients, but more significant improvements were found in the main groups 1 and 2 (Table 1). Thus, pain syndrome in the form of a feeling of heaviness and discomfort in the right hypochondrium, which is present in $45.5 \pm 2.1\%$ and $43.6 \pm 3.1\%$ of patients in main groups 1 and 2, respectively, after the end of 2 months of taking "Saumal" (main group 1) and "Saumal + Ursosan" (main group 2) did not disturb the patients. In the control group, this syndrome persisted after treatment in $10.5 \pm 1.8\%$ of patients ($p < 0.01$).

Table 1 - Baseline and control clinical parameters

No.	Clinical parameters/ syndromes	Main group 1 Saumal (n=28)		Main group 2 Saumal+Ursosan (n=27)		Control group Ursosan (n=19)	
		Baseline (%)	After treatment (%)	Baseline (%)	After treatment (%)	Baseline (%)	After treatment (%)
1	Pain syndrome	45.5±2.1	-	43.6±3.1	-	42.1±2.0	10.5±1.8**
2	Asthenic syndrome	86.4±2.2	40.9±2.2**	88.7±2.9	39.5±2.8**	89.5±2.1	73.7±2.3
3	Dyspeptic syndrome	77.3±2.3	36.4±2.3**	80.6±2.8	38.2±3.1**	84.2±2.4	63.2±2.4*
4	Hepatomegaly	90.9±2.4	77.3±2.8	85.7±3.2	74.2±2.9	73.7±2.3	73.7±2.3

* - The difference in dynamics since the beginning of therapy is significant ($p < 0.05$)

** - The difference in dynamics since the beginning of therapy is significant ($p < 0.01$)

After the course of treatment in the main groups 1 and 2, asthenic and dyspeptic syndromes significantly decreased ($p < 0.01$), and in the control group, the decrease in these parameters was insignificant compared to the main group: asthenic syndrome decreased insignificantly ($p > 0.05$), whereas decline of the dyspeptic syndrome was statistically significant, but less profound than in the main groups ($p < 0.05$). Hepatomegaly detected based on ultrasound examination (US) before treatment with "Saumal" and "Saumal + Ursosan" was observed in $90.9 \pm 2.4\%$ and $77.3 \pm 2.8\%$ of patients, respectively, and after the therapy its frequency decreased by 13.6% and 11.5%, amounting to $77.3 \pm 2.8\%$ and $77.3 \pm 2.8\%$, respectively ($p > 0.05$). A study in the control group demonstrated that "Ursosan" alone had little or no effect on hepatomegaly.

In laboratory research, an improvement in biochemical parameters in the studied groups was also revealed, but more pronounced changes were observed in experimental groups 1 and 2 (Table 2). Thus, in these groups, all biochemical parameters gradually decreased or normalized over the course of 2 months while taking Saumal in combination with UDCA. The ALT and AST cytolysis indices significantly decreased relative to the beginning of treatment both in the main group 1 ($p < 0.01$ and $p < 0.05$, respectively) and in the "Saumal + Ursosan" group ($p < 0.01$ in both groups). Cytolysis indices in the Ursosan control group also decreased compared to the beginning of treatment but were statistically insignificant ($p > 0.05$).

Table 2 - Baseline and control biochemical parameters

Biochemical parameters	Main group 1 Saumal (n=28)				Main group 2 Saumal+Ursosan (n=27)				Control group Ursosan (n=19)			
	Baseline (%)	After 2 weeks	After month	After 2 month	Baseline (%)	After 2 weeks	After month	After 2 month	Baseline (%)	After 2 weeks	After month	After 2 month
ALT	68.9±7.3	57.1±0.2	49.1±7.7	43.1±4.6**	74.5±8.4	61.2±7.1	55.3±5.2	45.7±5.4**	81.7±37.6	61.2±8.8	46.7±7.7	41.8±8.1
AST	46.9±4.9	38.3±6.1	33.3±4.2	30.5±3.5*	69.7±6.7	59.2±8.8	46.7±7.7	35.8±8.1**	66.3±32.3	39.2±7.3	35.3±5.1	32.7±5.4
Bilirubin total	13.8±1.9	12.3±2.0	12.9±2.4	11.8±2.2	15.2±2.4	14.8±2.2	12.9±1.2	12.8±2.2	13.8±2.3	14.6±2.1	11.4±1.8	12.5±2.2
Bilirubin direct	5.6±0.8	5.5±0.8	6.6±1.1	6.0±0.7	5.8±1.1	4.9±1.0	4.3±0.6	4.8±0.9	5.1±1.1	4.1±1.0	3.3±0.6	3.8±0.9
GGT	66.3±9.8	50±6.4	47.1±7.4	43.6±5.8	77.5±9.5	63.3±6.8	56.5±5.8	45.1±4.5*	97.5±29.5	83.3±23.8	76.5±19.8	74.1±17.5*
ALP	95.7±2.1	96.2±0.8	99.7±4.4	90.1±5.9	103.5±9.9	101.0±9.4	99.2±9.5	99.7±10.0	123.5±12.9	120.0±13.4	116.2±9.4	119.7±10.2
Cholesterol	5.4±0.3	5.1±0.3	5.1±0.3	4.7±0.3	5.3±0.4	5.0±0.1	5.1±0.1	4.5±0.4	5.2±0.4	6.5±0.1	5.7±0.5	5.6±0.4
HDL	1.8±0.3	1.8±0.4	2.0±0.5	1.5±0.3	1.7±0.3	1.7±0.4	1.8±0.3	1.9±0.4	1.7±0.4	1.7±0.4	1.6±0.4	1.5±0.4
LDL	3.1±0.2	3.1±0.2	2.9±0.4	2.8±0.3	3.5±0.4	3.5±0.2	3.0±0.5	2.5±0.2	3.8±0.5	3.8±0.5	4.2±0.5	4.0±0.5
TG	2.2±0.2	2.0±0.2	1.8±0.3	1.9±0.3	2.4±0.2	2.4±0.1	2.0±0.3	1.8±0.2	2.6±0.3	2.8±0.3	2.4±0.3	2.6±0.3
Glucose	5.8±0.3	5.8±0.3	5.8±0.3	5.6±0.3	5.7±0.4	5.3±0.6	5.4±0.5	5.4±0.4	5.2±0.5	5.1±0.5	5.2±0.3	5.0±0.3
* - The difference in dynamics since the beginning of therapy is significant (p < 0.05)												
** - The difference in dynamics since the beginning of therapy is significant (p < 0.01)												

Moreover, in all 3 investigation groups, there was a decrease in such indicators of cholestasis as GGT and ALP. Moreover, in the groups "Saumal + Ursosan" and "Ursosan", the decrease in GGT was statistically significant ($p < 0.05$), which confirms the anticholestatic effect of UDCA. The decrease in ALP in all groups at the end of treatment was not statistically confirmed ($p > 0.05$).

A very important and challenging property of mare's milk is its positive effect on cholesterol exchange. In this study, a decrease in cholesterol, LDL, and TG in the Saumal and Saumal + Ursosan groups was observed, probably due to the cholesterol-lowering and bifidogenic properties of Saumal (Table 2). In the control group of patients, no change in these parameters was observed, which is typical for UDCA.

Fibroelastometric examination of liver tissue using the "Fibroscan 502 TouchCAP" unit revealed different dynamics of fibrosis and steatosis indicators during therapy (Table 3). In the main groups of studies 1 and 2, a decrease in the degree of liver steatosis by 23.2 and 16.9 dB/m, respectively, was revealed. These changes were statistically insignificant, but there is an opinion, they were quite considerable when taking mare's milk for only 2 months. For comparison, in the control group "Ursosan" there was no decrease in steatosis, but on the contrary, there was a certain tendency to its increasing. Also, in all studied groups, there was a tendency towards a decrease in liver fibrosis.

Table 3 - Baseline and control fibroelastometric parameters

Fibroelastometric parameters	Main group 1 Saumal (n=28)		Main group 2 Saumal+Ursosan (n=27)		Control group Ursosan (n=19)	
	Baseline (%)	After treatment (%)	Baseline (%)	After treatment (%)	Baseline (%)	After treatment (%)
Stage of fibrosis (kPa)	5.4±0.4	4.98±0.31	7.09±6.9	5.7±0.4	7.3±0.6	6.7±0.5
Degree of steatosis (dB/m)	326.3±36.1	303.1±29.9	296.7±30.1	279.8±28.5	338.5±31.9	339.4±29.7

Thus, the conducted clinical study showed a significant improvement in the clinical-biochemical, ultrasound, and fibroelastometric parameters of NASH against the background of taking SMM "Saumal". At the same time, a comparative study showed that the effectiveness of mare's milk was higher than the effectiveness of conventional

ursodeoxycholic acid (Ursosan), which is included in the clinical guidelines and protocols for the management of NAFLD as an effective hepatoprotective agent.^(4,21,22) Besides, some randomized clinical trials have shown a positive result from the use of UDCA in NASH,^(9,23,24,25,26) in which the severity of inflammation syndrome and hepatic steatosis decreased.

Taking mare's milk not only normalized liver biochemical parameters but also decreased cholesterol metabolism (total cholesterol, LDL, TG), the degree of liver steatosis, and existing hepatomegaly declined too. This pleiotropic effect of mare's milk points to the pathogenetic feasibility for the use of Saumal in NAFLD, including NASH.

Apart from the aforesaid, there are conflicting opinions in the literature regarding the effectiveness of UDCA in NAFLD.^(27,28) According to these researchers, the use of UDCA did not have a significant effect on inflammation, steatosis, and liver fibrosis in NASH. The ineffectiveness of ursodeoxycholic acid in NASH has also been mentioned in European and American clinical guidelines.^(29,30) It follows from these protocols that the use of UDCA in NASH for 2 years did not lead to a decrease in inflammation and an improvement in the histological picture of the liver compared to control. These facts once again confirm the effectiveness of the use of mare's milk in this pathology in comparison with UDCA.

Conclusions

Mare's milk is a more effective therapeutic and prophylactic agent for NASH in comparison with ursodeoxycholic acid, which is included in Kazakhstan and Russian clinical treatment protocols. At the same time, Saumal not only developed hepatoprotective properties but also revealed its hypocholesterolemic and lipotropic effects. Considering the existing pleiotropic effect of mare's milk, we believe that its use in NASH is pathogenetically justified, and Saumal can take its rightful place in clinical guidelines and protocols for the treatment of NAFLD as a therapeutic and prophylactic agent.

Bibliographic references

1. Rinella ME, Sanyal AJ. Management of NAFLD: a stagebased approach. *Nat Rev Gastroenterol Hepatol.* 2016 [acceso: 24/02/2016];13:196-205. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/26907882/>

2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016 [acceso: 22/02/2016];64:73-84. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/26707365/>
3. Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. *New England Journal of Medicine*. 2017 [acceso: 23/11/2017];377(21):2063-72. Disponible en: <https://www.nejm.org/doi/full/10.1056/NEJMra1503519>
4. Ivashkin VT, Mayevskaya Marina V, Pavlov ChS, Tikhonov IN, Shirokova YeN, Buyeverov AO, *et al.* Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. // *Russian Journal of Gastroenterology, Hepatology and Coloproctology*. 2016 [acceso: 27/06/2017];2:24-42. Disponible en: https://www.gastro-j.ru/jour/article/view/31?locale=en_US
5. Maevskaya EA, Kucheryavyy YA, Maev IV. Intestinal microflora and non-alcoholic steatohepatitis: from mechanisms of pathogenesis to pathogenetic therapy. *Attending Physician*. 2014 [acceso: 27/06/2017]. Disponible en: <https://www.lvrach.ru/2014/08/15436028>
6. Vajro P, Paoletta G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. *Journal of Pediatric Gastroenterology and Nutrition*. 2013 [acceso: 05/05/2013];56(5):461-8. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/23287807/>
7. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. *Annals of Hepatology*. 2012 [acceso: 22/07/2012];11(4):440-9. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/22700625/>
8. Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. *Hepatoma Res* 2021;13;7:11. DOI: <https://doi.org/10.20517/2394-5079.2020.134>
9. Komshilova KA, Troshina EA, Butrova SA. Non-alcoholic fatty liver disease in obesity. *Obesity and Metabolism*. 2011 [acceso: 11/07/2011];3:3-11. <https://cyberleninka.ru/article/n/nealkogolnaya-zhirovaya-bolezn-pecheni-pri-ozhirenii/viewer>
10. Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for

treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. *Liver Int.* 2012;32(5):701-11. DOI: <https://doi.org/10.1111/j.1478-3231.2011.02730.x>

11. Zhangabylov AK. Saumal, koumiss-medicinal properties. Riga: Lamber Academia Publishing House; 2018 [access: 27/08/2018]. Disponible en: <https://www.morebooks.de/store/gb/book/isbn/978-3-659-51935-2>

12. Bimbetov B, Zhangobylov A, Aitbaeva S, Benberin V, Zollmann H., Musaev A, *et al.* Mare's milk: therapeutic and dietary properties. *Bulletin of the National Academy of Sciences of the Republic of Kazakhstan.* 2019 [acceso: 10/06/2019];3(379):52-58. Disponible en: <https://journals.nauka-nanrk.kz/bulletin-science/article/view/1460>

13. Bimbetov B, Zhangobylov A, Aitbaeva S, Bakytzhanuly A. The mare's milk application in non-alcoholic fatty liver diseases. *Medicine (Almaty).* 2019 [acceso: 14/11/2019];9(207):66-72. Disponible en: <https://www.medzdrav.kz/images/magazine/medecine/2019/2019-9/66-72.pdf>

14. Kushugulova A, Kozhakhmetov S, Sattybayeva R, Nurgozhina A, Ziyat A, Yadav H, *et al.* The mare's milk as a prospective functional product. *Functional foods in Health and disease.* 2018 [acceso: 08/11/2018];8(11):537-43. Disponible en: https://www.researchgate.net/publication/332232748_Mare's_milk_as_a_prospective_functional_product

15. Kanareikina SG, Davydova AA, Kanareikin VI. Therapeutic and prophylactic properties of mare's milk S.G. *Bulletin of beef cattle breeding.* 2016 [acceso: 24/06/2016];3(95):99-103. Disponible en: <https://cyberleninka.ru/article/n/lechebno-profilakticheskie-svoystva-kobyliego-moloka/viewer>

16. Mazhitova A, Kulmurzaev A. Physiologically functional components of mare's milk. *Journal of Engineering Manas.* 2015 [acceso: 01/10/2015];3(2):1-8. Disponible en: <https://dergipark.org.tr/en/pub/mjen/issue/40443/484321>

17. Brezovečki A, Čagalj M, Antunac N, Mikulec N, Bendelja DL. Production, composition and properties of mare's milk. *Dairy products.* 2014 [acceso: 01/04/2014];64(4):217-22. Disponible en: https://hrcak.srce.hr/index.php?show=clanak&id_clanak_jezik=191960

18. Markiewicz-Keszycka M, Wójtowski J, Czyzak-Runowska G, Kuczyńska B, Puppel K, Krzyżewski J, *et al.* Concentration of selected fatty acids, fat-soluble vitamins and b-

- carotene in late lactation mares' milk. International Dairy Journal. 2014 [acceso: 29/09/2014];38(1):31-6. Disponible en: <https://www.sciencedirect.com/science/article/abs/pii/S095869461400079X?via%3Dihub>
19. Kudayarova RR, Gilmutdinova LT, Yamaletdinov KS, Gilmutdinov AR, Gabdelhakova LT, Zinnatullin RKh. Historical aspects of the use in medicine kumis. Bulletin of Siberian Medicine. 2010. [acceso: 05/09/2010];5:186-190. Disponible en: <https://bulletin.tomsk.ru/jour/article/view/1685>
20. Zollmann H. Production of bio-mare's milk, koumiss and their use in Europe. Materials of the international congress "Gastroenterology-2015" Modern problems of pediatric and adult gastroenterology. From scientific achievements to clinical practice. Almaty; 2015.
21. Directory of diseases Med Element. Fatty degeneration of the liver. 2015 [acceso: 28/09/2020]. Disponible en: <https://diseases.medelement.com/disease/жировая-дегенерация-печени-k76-0/4827>
22. Republican Center for Healthcare Development of the Ministry of Healthcare of the RK. Non-alcoholic fatty liver disease in adults. Clinical protocol for diagnosis and treatment. 2015 [acceso: 28/09/2020]. Disponible en: <https://diseases.medelement.com/disease/неалкогольная-жировая-болезнь-печени-у-взрослых/14501>
23. Polosukhina A., Vinnitskaya EV, Khaimenova TY, Sandler YG. Non-alcoholic steatohepatitis: the problem of modern diagnostics. Consilium Medicum. Gastroenterology (Annex.). 2018 [acceso: 24/01/2018];1:23-9. Disponible en: <https://www.elibrary.ru/item.asp?id=35076970>
24. Nikonov EL, Aksenov VA. Modern approaches to the diagnosis and treatment of non-alcoholic fatty liver disease. Preventive Medicine. 2018 [acceso: 21/03/2018];3:62-9. Disponible en: <https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2018/3/1230549482018031062>
25. Tsukanov VV, Vasyutin AV, Tonkikh YL. Modern principles of management of patients with non-alcoholic fatty liver disease. Doctor Ru. 2019 [acceso: 12/04/2019];3(158):11-4. Disponible en: <https://journaldoctor.ru/catalog/gastroenterologiya/sovremennye-printsipy/>

26. Naydanova EG., Kozlova NM. The main directions in the treatment of non-alcoholic fatty liver disease. Bulletin of the Buryat State University. 2015 [acceso: 24/12/2015];12:123-9. <https://cyberleninka.ru/article/n/osnovnye-napravleniya-v-lechenii-nealkogolnoy-zhirovoy-bolezni-pecheni>
27. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, *et al.* High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebocontrolled trial. Hepatology. 2010 [acceso: 23/07/2010];52:472-9. Disponible en: <https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.23727>
28. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, *et al.* Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clinical Gastroenterology, Hepatology. 2006;4:1537-43. [access: 04/12/2006]. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/17162245/>
29. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). Clinical practice guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease. Journal of Hepatology. 2016 [access: 06/04/2016];64:1388-1402. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/27062661/>
30. Chalasani N, Younossi Z, Lavine JE, Mae Deiehl A, Brunt EM, Cusi K, *et al.* The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012 [access: 06/04/2012];142:1592-1609. Disponible en: <https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.25762>

Conflict of interests

The authors declare no conflict of interest.

Author's contributions

Bakytzhan Bimbetov: Conducting research

Nasrulla Shanazarov: Conducting research

Saule Aitbaeva: Reviewed the literature.

Abay Bakytzhanuly: Recruiting patients for research

Gulmira Utepbergenova: Statistical processing.